In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will get ABBV-744 and ruxolitinib. Members will obtain treatment until condition progression or even the participants are unable to tolerate the study drugs. - Participant eaten grapefruit or grapefruit products within 3 days previous to the https://abbv-744inclinicaltrialsf79013.theobloggers.com/38120187/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know